The statement in Pfizer report was "Collection of phase 2/3 data on vaccine immunogenicity and the durability of the immune response to immunization is ongoing, and those data are not reported here". These data's completeness is not defined by me, but by their trial organizer. I can't see how I or anyone could change that definition.
Again, it is not about completeness. It is about continuation. Many people can study the same subject for decades. For each publication, it is always only one aspect of many components that can go on for decades. In fact, I am 120% sure that these subjects WILL be followed closely for as long as possible, decades if possible. And you will continue to see their publications in the years to come. In that sense, it is never complete. Take aspirin for example. If you search aspirin, a drug that was made in 1899, people keep finding new side effects and new uses of aspirin. Even a few years back, Harvard published a new aspirin clinical trial that followed 30,000 nurses for 20 years and evaluated side effects and the ability of aspirin to prevent cancer. Is that complete? That study says nothing about the cardiovascular effects of aspirin. Is it complete? In the grand scheme of things, it is not. But for the purpose that particular study, it is complete. In the case of the Pfizer and Moderna clinical trials, the goal of the published study was exactly for a short-term (3 month) clinical trial. For that purpose, that study is complete.
Please just keep in mind that this is usually and typically done in biology/medicine. There is no conspiracy in it. No one is trying to intentionally mislead people. Given the difficult situation, this is the best anyone can do. I myself cannot think of another way.
Again, their goal is to roll out the short-term efficacy and safety as soon as possible. They need this kind of information to decide whether they should give these vaccines to the people with highest risk so as to save their lives. One more day they spend to wait means another 4000 lives lost on that day. And one more day they wait means another chance the virus gets to mutate to a new form to escape the vaccines. So they need the short-term efficacy and safety ASAP to decide that decision. And that's the exact goal of that study. They achieved it and published it. Once they settle that most urgent question, they can take a breather and wait a little while for the less urgent data. This is a way of damage control.
All clinical trials are done in this way. Chinese ones, American ones, German ones, etc. When the Chinese ones come out, you will see that they are done in the exact same way. As I said before, a Chinese phase 3 trial didn't even include subjects older than 59. Is that complete? No, we have many many people older than 59. But that's their design based on their initial plan for how they wanted to implement their vaccination protocol. They wanted to exclude the group >59, in order to speed up the vaccination process. Incomplete? Yes. But still an effective way to implement their vaccination program.
